Antiangiogenic properties of metronomic chemotherapy in breast cancer. - Wikidata - awgldk - TriplyDB

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

http://www.wikidata.org/entity/Q36768296

about

Phosphorescence monitoring of hypoxic microenvironment in solid-tumors to evaluate chemotherapeutic effects using the hypoxia-sensitive iridium (III) coordination compound Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer.Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.Maintenance treatment in metastatic breast cancer.Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.

P2860

Q28544651-C149CBA2-428F-44F6-85D4-07C2E4F561C2 Q33403308-70ACF234-B6A2-47F1-B3A1-7941060B6C52 Q33780689-9FF49515-060F-4F3E-9AF3-518D02D53020 Q35776220-D78EBB5A-AA02-4B30-9A77-3EC673617991 Q35872701-330A13DA-69A7-4F7E-897F-490844521680 Q36802689-6AC13C45-44A1-471A-BE05-F94EEB81EF44 Q37338245-3B054A36-35DF-4684-8BAE-AE959B48FDFA Q37528441-12101583-98CC-41B7-AA3C-184BBB7AC740 Q37565155-AE6B6D44-8692-4A62-8D77-EDB30AE84C23 Q41742917-C6038C90-F1A7-4AFB-9A59-DA2BE90920EF

P2860

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

http://www.wikidata.org/entity/Q36768296

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

@ast

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

@en

type

label

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

@ast

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

@en

prefLabel

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

@ast

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

@en

P1433

Q36768296-E9CAC5BB-D86A-431B-A24D-148133192BD8

P1476

Q36768296-EF6CDB7F-52DD-473B-8876-89966862B1B3

P2093

Q36768296-0CEF0F0A-DB73-4127-B1BF-190303F97F3D

Q36768296-4692F6F4-D166-41C5-B74F-63A8F15A9EB7

P2860

Q36768296-02295F35-53BA-43F0-922A-7320B9634080

Q36768296-12974383-7FF7-4CC2-AEF6-9D761D35C12C

Q36768296-158C1C08-634F-4F33-B310-9F6A64B23D69

Q36768296-50395872-E8E6-49AE-80DC-567985B38D1E

Q36768296-5A1D81FE-668D-4DE6-8AFB-BEEF1B1F29CB

Q36768296-656EBB0C-BA1B-43A3-8A57-701FB6088EEA

Q36768296-6BAC0C71-785B-4E4E-A847-DD0D65C4849B

Q36768296-74CD3C30-2C84-4218-8494-6EB5ABF7C802

Q36768296-817E6E4F-8F0A-40A4-B9E5-6C4AFE75ED2D

Q36768296-82DA791A-42A5-45B4-ADB4-0EF7D88DC554

P304

Q36768296-8ACBC87B-6950-4C20-8D42-51A0CD34F44A

P31

Q36768296-41A1BB88-313C-4B6B-B4E9-A0811E642563

P356

Q36768296-5971B4B3-698E-485E-B358-128CF3721135

P407

Q36768296-4C988722-1747-45A3-A9C6-064665D4C1E4

P433

Q36768296-1ABAEC46-6653-497F-97C7-9A56C2039A76

P478

Q36768296-71212697-B50A-42D8-B7F1-E66C8EC95E49

P50

Q36768296-6A776178-ACE8-4AD9-985B-113EBF49C8A8

Q36768296-CA168569-74A8-49BA-B2CE-DEB0E9C895C5

Q36768296-F62A22D5-E313-4DE4-8F73-723251FA23F9

P577

Q36768296-249F0117-B268-4ED1-9095-551BE1C2C17E

P698

Q36768296-AE220B12-CC1E-4A17-979A-3BD655EFBC6D

P921

Q36768296-EBEA6E7F-3D9C-4C7E-864B-CA1A77F384B4

P356

14796694.3.2.183

P1433

Future Oncology

P1476

Antiangiogenic properties of metronomic chemotherapy in breast cancer

@en

P2093

Gaia Schiavon

http://www.w3.org/2001/XMLSchema#string

Marianna Silletta

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.

Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

P304

183-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14796694.3.2.183

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Santini

Giuseppe Tonini

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17381418

http://www.w3.org/2001/XMLSchema#string

P921